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Background: Novel parameters derived from peak maximal oxygen uptake (VO2) and exercise arterial blood
pressure, such as peak circulatory power (CP) and exercise cardiac power (ECP), can be used in the risk assessment
of cardiovascular disease and stroke. However, the determinants of these factors are poorly characterized in the
general population.
Methods: We assessed peak arterial blood pressure, CP and ECP with standardized cardiopulmonary exercise test
(CPET) on 281 female and 257 male participants of the Cardiovascular Risk in Young Finns Study. The subjects were
aged 30–47 years. Peak VO2 as well as systolic and diastolic arterial blood pressures were measured to calculate
peak mean arterial pressure, CP and ECP. These parameters were assessed for correlation with sex, age, height,
weight, waist-to-hip ratio, smoking, physical activity index (PAI), fasting insulin and glucose levels as well as the use
of antihypertensive treatment.
Results: Sex, age and weight explained 36% of the variation in peak systolic blood pressure, and these factors in
combination with height and the use of antihypertensive treatment explained 13% of the variation in peak diastolic
blood pressure. Sex, height, weight, waist-to-hip ratio, PAI and smoking explained 49% − 52% of the variation in
peak CP. Sex, age, height, weight, waist-to-hip ratio, PAI, smoking and insulin levels explained 21% − 49% of
variation in ECP.
Conclusions: Subject demographics and lifestyle-related factors should be taken into account when exercise blood
pressure response, CP and ECP are used to evaluate patients’ cardiac function in CPET.
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Table 1 Subject characteristics
Parameter Female Male
(n = 281) (n = 257)
Age (y) 38.9 ± 5.0 38.2 ± 5.1
Height (cm) 166 ± 5.4 180 ± 6.4
Weight (kg) 70.5 ± 13.6 86.9 ± 14.6
BMI (kg/m2) 25.7 ± 5.1 26.9 ± 4.2
Waist-to-hip ratio 0.85 ± 0.06 0.94 ± 0.076
SBP (mmHg) 123 ± 14 133 ± 14
DBP (mmHg) 79 ± 9 84 ± 11
MAP (mmHg) 99 ± 10 101 ± 10
Fasting glucose (mmol/L) 5.2 ± 0.69 5.5 ± 0.68
Fasting Insulin (mmol/L) 8.6 ± 7.0 9.3 ± 10.9
PAI 8.8 ± 1.8 8.7 ± 2.0
FEV1/FVC (%) 80.7 ± 5.5 78.8 ± 5.9
Antihypertensive treatment (%) 5.0 4.3
Smoking (%) 11.0 15.2
Values are mean ± SD if not otherwise indicated.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood
pressure; MAP: mean arterial pressure; PAI: physical activity index; FEV1/FVC:
ratio of forced expiratory capacity in one second and forced vital capacity.
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Peak oxygen uptake (VO2) is a measure of the of the car-
diovascular system’s functional capacity [1]. Peak VO2,
exercise blood pressure (BP) response and several other pa-
rameters related to cardiovascular fitness can be assessed
easily with a cardiopulmonary exercise test (CPET) [1-6].
Low maximal aerobic capacity predicts, to an extent,
cardiovascular events, morbidity and mortality in later life
[7-10]. In addition to peak systolic blood pressure (SBP),
peak diastolic blood pressure (DBP), mean arterial blood
pressure (MAP), and oxygen pulse (VO2/heart rate [HR]),
some novel parameters such as peak circulatory power
(CP) and exercise cardiac power (ECP) have been suggested
to improve the prognostic accuracy of a CPET [5,11-16].
CP, expressed as peak VO2 multiplied by peak SBP or
MAP, represents the volume of O2 added to the mixed
venous blood by the lungs and transferred to systemic ar-
terial circulation, against a pressure gradient, by the heart
[5,17]. As the gradient through which the O2 is transferred
by the heart is SBP as opposed to MAP, CP also relates to
an instantaneous peak work of the cardiac cycle [5,17]. It
has also been suggested that if CP is calculated as the
product of peak VO2 and MAP rather than SBP, it may
rule in the cardiac afterload more accurately [11,17].
Another non-invasive surrogate for cardiac power output
is exercise cardiac power (ECP), which is the product of
peak VO2 (expressed as a percent of predicted) and peak
SBP. ECP combines exercise SBP as an estimate of afterload
with peak VO2 as an estimate of peak cardiac output
neglecting preload [6,13]. When ECP is normalized against
subject demographics by expressing peak VO2 as a percent-
age of predicted VO2 (i.e. by using reference value equa-
tions), the prognostic value of each indicator is improved
and ECP serves as an independent predictor of mortality
and morbidity in congestive heart failure [6]. The integra-
tion of peak VO2 with SBP by analyzing the ratio of these
parameters improves the predictive power of stroke-risk as-
sessment as well [13].
As mentioned above, peak VO2, peak BP response, and
several parameters derived from these factors have a
marked prognostic significance. However, the determinants
and levels of CP and ECP have not been characterized pre-
viously in a general population. Therefore, we carried out
CPETs for a sample of 538 subjects drawn from the Cardio-
vascular Risk in Young Finns Study and explored peak SBP,
DBP, MAP, CP and ECP in relation to sex, age, height,
weight, waist-to-hip ratio, smoking, physical activity index




The Cardiovascular Risk in Young Finns Study is an on-
going follow-up study on the precursors of atherosclerosisin Finnish children and adolescents. The first cross-
sectional survey was conducted in 1980 when 3,596 par-
ticipants aged 3, 6, 9, 12, 15 and 18 years were randomly
chosen from the national population register to represent
each (geographical) area in Finland [18]. The sample was
fairly representative of the entire Finnish population. The
fourth follow-up study was conducted in 2007 with 2204
participants. Of those, 538 individuals (257 males and 281
females) aged from 30 to 47 years volunteered for a car-
diopulmonary exercise test (CPET) during the years 2007
to 2009. The characteristics of the participants in the
2007–2009 cross-section are presented in Table 1. The
study was approved by the ethics committee of the
Tampere University Hospital, and all subjects gave their
written informed consent.
Clinical characteristics and risk factors
Height, weight as well as waist and hip circumferences
were measured, and the waist-to-hip ratios were calculated.
Smoking habits were assessed with a questionnaire, and
smoking was modeled as a dichotomous variable (smo-
king/non-smoking) defined as regular cigarette smoking
on a daily basis or more frequently. To measure physical
activity, a short self-report questionnaire was administered
for the subjects. The questions involved the intensity of
physical activity, frequency of vigorous physical activity,
hours spent on vigorous physical activity, average duration
of a physical activity session and participation in organized
sports. A physical activity index (PAI) ranging from 5 to 15
was calculated as a sum score of these items. The lowest
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active. The original description of the method has been
published previously [19]. Plasma glucose and insulin con-
centrations were measured using standard methods [20].
The demographic, clinical and laboratory data on the sub-
jects are presented in Table 1.
Cycle ergometry, spirometry and gas measurements
Exercise tests were performed on electronically braked cycle
ergometers (Lode Corival 906900, Lode BV, Groningen,
Netherlands) according to the American Thoracic Society
(ATS) guidelines and the American College of Chest
Physicians (ACCP) Joint Statement on Cardiopulmonary
Exercise Testing [1]. In brief, after a 10-minute rest and a
warm-up period of 10–60 seconds, the subjects performed
an incremental test with 1-minute intervals and incre-
ments of 15 W/minute for women and 20 W/minute for
men until exhaustion limited maximal power output.
Otherwise, objective test termination criteria (established
in ref. [1]) were applied by the observers. Standard 12-lead
electrocardiography (ECG) was recorded during the test
(Corina ECG amplifier and CardioSoft acquisition soft-
ware ver. 4.2, GE Medical Systems, Freiburg, Germany).
BP was measured with the cuff method by means of aus-
cultation. The mean arterial pressure was calculated using
the formula: (SBP + 2* [DBP])/3 as suggested elsewhere
[11]. Peak HR was defined as the maximal heart rate
achieved during the exercise. The rating of perceived exer-
tion was obtained using the Borg category scale [21]. In
order to assess forced vital capacity (FVC) and forced
expiratory volume in the first second (FEV1), a standard
flow-volume spirometry measurement was performed
with a calibrated spirometer (V-max 29C, SensorMedics,
Yorba Linda, CA, USA) according to the ATS and the
European Respiratory Society (ERS) Task Force guidelines
[22]. Breath-by-breath measurements of VO2 and carbon
dioxide output (VCO2) as well as a measurement of venti-
latory parameters were performed with computerized
analyzers (V-max 29C, SensorMedics, Yorba Linda, CA,
USA and Jaeger Oxycon Pro, VIASYS Healthcare GmbH,
Hoechberg, Germany). As two different analyzers were
used, the linearity of the gas measurement devices was
checked prior to the analyses with a metabolic simulator
(VacuMed Syringe model 17050 calibration kit, Ventura,
CA, USA) at the ventilation levels of 34–90 liters/min.
This calibration method has been proven valid [23]. The
correlation between expected and measured values at this
test range suggested good linearity for both devices
(R2 values for VO2 and VCO2 measurements > 0.99). The
inter-instrument difference varied from 1% to 3% for tidal
volume measurements, VO2 and VCO2 which is within
the expected range [1]. After calibration measurements,
O2 and CO2 test gases were used daily in order to check
the reproducibility of the measurements. The final tabularand graphic averaged data were collected at 30-second in-
tervals as recommended [1]. Peak VO2 was determined as
the highest VO2 during the last 30-second averaged inter-
val. Peak work rate (WR) was calculated by adding the
WR during the last full one-minute interval to the fraction
of the work performed over the final, exhaustion-limited
(interrupted) interval. The expected peak HR was calcu-
lated using the formula 220 minus age (years). Standard
published equations were applied to generate predicted
values for peak VO2 [24-26]. CP was calculated as the
product of peak VO2 (expressed in mL/kg/min) and peak
SBP (expressed as mmHg) at the last BP measurement
[5,12,14], or, alternatively, as the product of peak VO2
(mL/kg/min) and MAP (mmHg) [11,16]. ECP [6] was ori-
ginally calculated as the product of peak SBP (mmHg) and
peak VO2 expressed as a percentage of the predicted peak
VO2 (%) by the equation provided by Wassermann et al.
[26]. This predictive equation for VO2 rules in age, weight
and sex. In order to improve the generalization of the re-
sults, we also calculated the percentage of predicted VO2
using alternative reference value equations, namely those
from the European SHIP- study [25], which take into
account age, sex, and body mass index (BMI), and the
North American equation by Jones et al. [24], which strati-
fies the predicted VO2 by age, sex and height. As there is
one previous key study that integrates SBP with peak VO2
by the ratio of these parameters, we also explored these
figures [13].
While all subjects carried out the cycle ergometer test
and reached the objective maximum (based on respiratory
quotient > 1.0, peak HR at the range of expected maxi-
mum of HR ± 10 or Borg category scale >19), we decided
to exclude gas measurement data for 8 subjects (1.5% of
tested individuals). The reason for this was technical error
such as mask leakage or computer failure. For one subject,
the gas measurements were interrupted, as the subject
could not tolerate the mask.
Statistical analysis
Numerical values are presented as means ± standard de-
viation (SD). Statistical analyses were initially carried out
using Statistica for Windows 6.0 (StatSoft Inc., Tulsa,
Oklahoma, USA), and PASW Statistics 18.0 for Windows
(SPSS Inc., Chicago, Illinois, USA), with Kruskall-Wallis
analysis of variance and the Mann–Whitney U-test. For
correlation analysis, the Pearson product–moment cor-
relation coefficient was calculated. After non-parametric
analyses variables potentially explaining peak SBP, DBP,
CP, and ECP were entered into a multivariable linear
regression model. The original covariates in the models
were sex, age, height, weight, waist-to-hip ratio, PAI,
smoking, fasting insulin and glucose, and the anamnestic
use of antihypertensive treatment. Values for insulin and
glucose were log-transformed before analyses, because of
Table 2 Cardiopulmonary exercise test values in men
and women
Parameter Female (n = 281) Male (n = 257)
Mean ± SD Mean ± SD
VO2 (mL/min) 1840 ± 458 3000 ± 632
VO2/kg (mL/kg/min) 26.5 ± 6.9 35.0 ± 7.8
SBP (mmHg) 189 ± 23 215 ± 24
DBP (mmHg) 91 ± 13 93 ± 13
MAP (mmHg) 124 ± 14 134 ± 15
CPSBP (mL/min/kg×mmHg) 4990 ± 1330 7490 ± 1780
CPMAP (mL/min/kg×mmHg) 3260 ± 855 4630 ± 988
ECPWasserman (%mmHg) 19100 ± 5080 20500 ± 4920
ECPKoch (%mmHg) 18800 ± 4900 21400 ± 4930
ECPJones (%mmHg) 18750 ± 5470 20500 ± 4820
VO2/SBP (mL/min/mmHg) 9.8 ± 2.6 14.1 ± 3.3
VO2 (% predicted)Wasserman 101 ± 24.6 96.0 ± 21.1
VO2 (% predicted)Koch 99.6 ± 24.0 100 ± 20.9
WR (W) 163 ± 28.9 261 ± 47.4
WR (% predicted) 119 ± 22.7 113 ± 18.9
VO2: oxygen consumption; SBP: systolic blood pressure; DBP: diastolic blood
pressure; MAP: mean arterial pressure; CP: circulatory power; ECP: exercise
cardiac power; WR: work rate. CP is given as a product of VO2 and systolic
blood pressure (CPSBP) as well as a product of VO2 and MAP (CPMAP). ECP is
presented using the alternative VO2 reference value equations provided by
Wasserman et al. [26], Koch et al. [25], and Jones et al. [24] and indexed
correspondingly in the table as ECPWasserman, ECPKoch, and ECPJones.
Values are shown as peak values and as a percentage of the predicted value.
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dered significant in all analyses.
Results
Determinants of peak aerobic capacity, SBP, DBP, MAP,
CP and ECP
The peak (mean ± SD) VO2 values for the whole cohort
were 2397 ± 799 mL/min (30.6 ± 8.49 mL/kg/min). Mean
WR was 209 ± 62.5 W. Mean peak SBP was 201 ±
27 mmHg, mean DBP 92 ± 13 mmHg, and mean MAP
129 ± 15 mmHg. Mean peak CP of the cohort was 6195 ±
1999 mL/min/kg*mmHg when expressed as the product of
VO2 and SBP and 3914 ± 1147 mL/min/kg*mmHg when
expressed as the product of VO2 and MAP. Mean ECP was
19801 ± 5047 %mmHg when the VO2 percentage of the
predicted value was calculated using the reference value
equation provided by Wassermann et al. [26], 20069 ±
5083 %mmHg when the equation from the SHIP-study
[25] was applied, and 19594 ± 5234 %mmHg when the
equation by Jones et al. [24] was applied. VO2/SBP [13]
was 11.9 ± 3.67 mL/mmHg. These figures as well as those
representing aerobic capacity (VO2 expressed as % of the
predicted value by Wasserman et al. [26] and Koch et al.
[25]) are presented separately for female and male subjects
in Table 2. Determinants of Peak VO2, SBP, DBP, MAP,
CP, and ECP are given in Table 3. In these tables, CP is
presented as the product of SBP and peak VO2, or alter-
natively, as the product of MAP and peak VO2. ECP is
expressed as the product of the percentage of the pre-
dicted VO2 value with three different reference value
equations [24-26], all of which distinctly stratify subject
demographics (see Methods). Moreover, the ratio of peak
VO2 and SBP is presented [13]. The suggested lower
limits (i.e. -2 SD levels) of peak SBP, DBP, MAP, CP, ECP,
and VO2/SBP are presented in Table 4.
Peak VO2, SBP, DBP, MAP, CP, and ECP were lower in
female than in male subjects (Table 2). Peak VO2 was
dependent on sex, height, weight, PAI, smoking, and fas-
ting insulin levels. Peak SBP was dependent on sex, age,
and weight. Peak DBP and MAP were dependent on sex,
age, height, and weight. Moreover, DBP was dependent on
the use of antihypertensive treatment. In addition, MAP
was dependent on fasting insulin levels. The major deter-
minants of peak CP were sex, height, weight, PAI, and
smoking. When SBP was used to calculate CP, the waist-
to-hip ratio had a small effect on this parameter (Table 3).
The estimates of CP that were based on peak VO2 and
SBP were very concordant with the estimates based on
peak VO2 and MAP (R2 0.96).
As mentioned earlier, we explored several alternative
ways to determine ECP (Table 3). All of the derivatives for
ECP were dependent on age, height, weight, PAI, and
smoking. When ECP was determined using the VO2 refe-
rence value equations provided by Jones et al. [24] orKoch et al. [25], or when ECP was expressed as a ratio of
peak VO2 and SBP, ECP was also dependent on sex.
When ECP was calculated using the VO2 reference value
equation provided by Wasserman et al. [26], ECP was
independent of sex, but clearly associated with the waist-
to-hip ratio. Moreover, fasting insulin levels had a small
effect on VO2/systolic blood pressure. Altogether, these
factors explained from 21% to 49% of the variation in ECP
indices (Table 3).
There was a good concordance between the ECP esti-
mates, when the VO2 reference values used to calculate
ECP were generated using the predictive equation pro-
vided by Wasserman et al. [26] or Koch et al. [25], the
R2-value being 0.94. Markedly lower concordance in
ECP values was found, when the reference values were
generated using the equation provided by Jones et al.
[24] or Wassermann et al. [26] (R2 0.67). Moreover, con-
cordance in ECP values was weak when the estimates
generated by the predictive equations by Jones et al. [24]
and Koch et al. [25] were correlated (R2 0.66).
Discussion
CPET provides a non-invasive, easily accessible and infor-
mation-intensive way to obtain parameters for the as-
sessment of cardiovascular status. Low peak VO2 and
Table 3 Determinants of peak VO2, SBP, DBP, MAP, CP, ECP, and VO2/SBP (multivariable regression)
Parameter VO2, SBP DBP MAP CPSBP CPMAP ECPWasserman ECPKoch ECPJones VO2/SBP
β ± SE β ± SE β ± SE β ± SE β ± SE β ± SE β ± SE β ± SE β ± SE β ± SE
Sex 675 ± 77.5‡ 18.4 ± 3.6‡ 4.3 ± 2.1* 9.1 ± 2.2‡ 2300 ± 235‡ 1370 ± 140‡ 237 ± 764 1770 ± 764* 2080 ± 753† 2.4 ± 0.4‡
Age −5.5 ± 4.5 0.8 ± 0.2‡ 0.5 ± 0.1‡ 0.6 ± 0.1‡ 10.2 ± 13.6 10.2 ± 8.1 238 ± 44.3‡ 153 ± 44.3‡ 193 ± 43.7‡ −0.07 ± 0.03†
Height 23.6 ± 3.9‡ −0.12 ± 0.18 −0.26 ± 0.11* −0.23 ± 0.1* 53.7 ± 11.9‡ 24.2 ± 7.2‡ 168 ± 38.6‡ 117 ± 38.6† −189 ± 38.0‡ 0.12 ± 0.02‡
Weight 10.9 ± 2.2‡ 0.42 ± 0.1‡ 0.13 ± 0.06* 0.21 ± 0.06† −29.4 ± 6.6‡ −21.0 ± 4.0‡ −59.7 ± 21.3‡ −46.5 ± 21.3* 136 ± 21.0‡ 0.03 ± 0.01*
WHR 32.3 ± 460 28.9 ± 21.4 9.3 ± 12.6 17.2 ± 13.4 −92 ± 1390 531 ± 836 1730 ± 4530 3100 ± 4530 4120 ± 4480 −0.80 ± 2.6
PAI 78.5 ± 11.6‡ 0.86 ± 0.54 −0.25 ± 0.32 0.07 ± 0.34 224 ± 35.1‡ 118 ± 21.0‡ 720 ± 114‡ 746 ± 114‡ 708 ± 112‡ 0.34 ± 0.07‡
Smoking −228 ± 63.2‡ 0.41 ± 2.9 0.52 ± 1.7 0.48 ± 1.8 −619 ± 192† −389 ± 114‡ −1790 ± 623† −1870 ± 623‡ −1710 ± 614* −1.1 ± 0.36†
Fasting insulin −9.3 ± 3.1‡ 0.26 ± 0.15 0.19 ± 0.1 0.25 ± 0.10* −17.9 ± 9.5 −11.4 ± 6.5 −49.0 ± 30.8 −53.1 ± 30.8 −53.0 ± 30.3 −0.05 ± 0.02†
Fasting glucose 26.8 ± 39.6 −1.1 ± 1.8 −2.0 ± 1.1 −1.9 ± 1.2 158 ± 120 48.9 ± 72.9 381 ± 390 266 ± 390 243 ± 385 0.12 ± 0.23
AHT −53.6 ± 96.8 2.4 ± 4.5 5.2 ± 2.6* 4.4 ± 2.8 −54.2 ± 294 9.6 ± 175 −327 ± 954 −114 ± 954 −486 ± 940 −0.39 ± 0.56
Whole Model R2 67% 36% 13% 26% 52% 49% 21% 21% 28% 49%
VO2: oxygen consumption; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; CP circulatory power, ECP: exercise cardiac power; WHR: waist-to-hip ratio; PAI: physical activity index;
AHT: antihypertensive treatment; β: regression coefficient for a 1-unit change in parameter; SE: standard error. CP is given as a product of VO2 and SBP (CPSBP) as well as a product of VO2 and MAP (CPMAP). ECP is
presented using the alternative VO2 reference value equations provided by Wasserman et al. [26], Koch et al. [25], and Jones et al. [24] and indexed correspondingly in the table as ECPWasserman, ECPKoch, and ECPJones.




















Table 4 Lower limits of peak exercise blood pressure,
circulatory power and exercise cardiac power
Parameter Female (n = 281) Male (n = 257)
Mean −2 SD level Mean −2 SD level
SBP (mmHg) 143 168
DBP (mmHg) 65 67
MAP (mmHg) 95 104
CPSBP (mL/min/kg×mmHg) 2330 3930
CPMAP (mL/min/kg×mmHg) 1550 2660
ECPWasserman (%mmHg) 8960 10700
ECPKoch (%mmHg) 9000 11600
ECPJones (%mmHg) 7820 10900
VO2/SBP (mL/mmHg) 4.57 7.52
SD: standard deviation; SBP: systolic blood pressure; DBP: diastolic blood
pressure; MAP: mean arterial pressure; CP: circulatory power; ECP: exercise
cardiac power; VO2: oxygen consumption.
CP is given as a product of VO2 and systolic blood pressure (CPSBP) as well as
a product of VO2 and mean arterial pressure (CPMAP). ECP is presented using
the alternative VO2 reference value equations provided by Wasserman et al.
[26], Koch et al. [25], and Jones et al. [24] and indexed correspondingly in the
table as ECPWasserman, ECPKoch, and ECPJones.
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have prognostic significance in patients with chronic heart
failure (CHF) [27,28].
Peak VO2 alone has been widely used as a substitute for
cardiac output (O2 flow). This parameter as an indicator
of cardiovascular capacity has the weakness of overlooking
cardiac afterload (i.e. systemic peripheral resistance). Peak
CP, as a surrogate of cardiac power, has been shown to
have better prognostic value in CHF than peak VO2,
VO2/HR and peak SBP alone [5,11]. Peak CP correlates
closely with cardiac output and cardiac power output at
peak exercise [16], making it a relatively good substitute
for these parameters provided that the arterial-venous
difference in O2 content is invariable [16,27]. The major
advantage of CP is that it is a simple and practical index
available non-invasively in connection with any CPET
without the need for special equipment. CP incorporates
information on arterial-venous difference, HR, stroke
volume and BP responses at peak exercise [11,12]. Physio-
logically, CP represents the volume of O2 added to the
mixed venous blood by the lungs and transferred to sys-
temic arterial circulation, against a pressure gradient, by
the heart [17].
In view of current literature, CP and ECP appear to be
promising and useful parameters in the assessment of
heart failure risk. To date, the current study is the first in
which data on the mean values and normal variation
(standard deviations) of CP and ECP is presented in young
adults. Therefore, our data, which is based on a cohort of
relatively young and healthy subjects of normal aerobic fit-
ness (Table 2) with a low prevalence of cardiovascular
medication, is of high value. In order to facilitate thegrading of these parameters, we present the lower limits
(−2 SD levels below the mean) of peak SBP, DBP, MAP,
CP, as well as ECP in Table 4.
There are several illustrative examples in the literature
of how CP can be used for the risk assessment of heart
failure. In a recent study on 19 women and 156 men aged
53 ± 10 years, CP was decreased to the level of 3198 mL/
min/kg*mmHg in patients with CHF, and was the best
predictor of outcome when assessed in a multivariable
model with peak VO2 [5]. It also appeared that markedly
declined CP is probably the best parameter for identifying
patients with a particularly poor prognosis, i.e. those with
reduced VO2 and reduced BP [5]. The CP- values in the
above-mentioned study were well below (−1.5 SD) the
mean of the levels observed in the young adults herein.
Similarly, in a recent independent study including 631
CHF patients (mean age 58 ± 10 years, 90% males) the
mean CP was 2425 mL/min/kg*mmHg, being higher in
those who were alive at the end of 3.8 ± 1.4 years follow-
up (2500 ± 866) than in those who died (1899 ± 774) [27].
These figures correspond to the −1.8 SD and −2.1 SD
limits of the peak mean CP in the current study. More-
over, low peak systolic blood pressure, CP and the pre-
sence of exertional oscillatory ventilation have been
shown to be superior in their predictive power when com-
pared with traditional CPET-based risk parameters such
as peak VO2, O2 pulse and VE/VCO2 slope [27]. A low
mean CP of 2605 ± 1198 mL/min/kg*mmHg (−1.8 SD
below the mean of the current study) has also observed
among 402 CHF patients (aged 55 ± 10 years), and CP was
a strong predictor of mortality with higher prognostic
value than peak SBP, VO2 and VE/VCO2 slope, irrespec-
tive of whether the patients were receiving β-blocker the-
rapy or not [14].
Even better prognostic value for CP was found in the
study by Giardiani et al. [11] including 432 patients with
adult congenital heart disease. In their study, the patients
having a low CP level of below 1476 mL/min/kg*mmHg
(calculated here as a product of peak VO2 and MAP) were
at a 15.4-fold higher risk of death than those with high CP
values. The 1476 L/min/kg*mmHg cut-off level in CP
is −2.1 SD lower than the mean CP among the young the
adults studied in the present study. Giardiani et al. further
showed that CP was the best predictor of mortality during
the 4.4-year follow-up. In their study, CP had higher prog-
nostic power than any of the other exercise parameters,
being independent of the subjects’ peak VO2 and chrono-
tropic response.
Jaussaud et al. [12] studied 36 patients (aged 60 ±
12 years), who were receiving cardiac resynchronization
therapy (CRT). The mean CP of patients before CRT treat-
ment was 1663 ± 494 mL/min/kg*mmHg (i.e. –2.0 SD
below the mean CP of the present young adults) and in-
creased to up to 2125 ± 1014 mL/min/kg*mmHg (+ 28%)
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the CP improved more in those patients who responded to
therapy (+ 42%) than in those who did not (+18%). Among
CRT responders, a rise in CP was associated with a 17%
rise in peak VO2, a 5% rise in peak SBP, a 20% rise in ma-
ximal WR and a 32% rise in ejection fraction. In addition
to a 47% decrease in mean end systolic left ventricular
volume, a 26% decrease in mitral regurgitation grade, and
a 17% decrease in VE/VCO2 slope was found [12]. As no
statistical difference was found in peak VO2, peak SBP,
maximal WR, and ejection fraction was found among
CRT non-responders, Jaussaud et al. suggested that CP,
along with ventilatory response, has the power to differen-
tiate CRT responders from the non-responders [12].
In a previous study of 500 patients with CHF, peak
SBP and VO2 - when analyzed as a percentage of pre-
dicted peak VO2 – significantly enhanced the risk strati-
fication of heart failure patients [28]. In our opinion, it is
preferable to use the percentage of predicted peak VO2
rather than absolute VO2 as a prognostic parameter, be-
cause it stratifies the aerobic capacity by age, sex, height,
weight, and BMI, i.e. by the factors that are included as
variables in the reference value equations.
The idea to use expected values to stratify subject demo-
graphics in risk estimation improves the diagnostic accu-
racy of ECP. In a recent study by Scharf et al. [6] which
included 154 CHF patients (88 % of whom were men,
mean age of cohort being 51 ± 0.8 years), the predictive
power of ECP (expressed as %mmHg) was better than that
of aerobic capacity (expressed as % of predicted peak
VO2) or peak SBP response alone [6]. ECP was the only
independent predictor of mortality when analyzed in a
multivariable regression model [6]. ECP <5000 %mmHg
(i.e. –2.8 to −3.0 SD below the mean of the present young
adults) indicated a 1-year mortality rate of 37% whereas
only 2% of the patients having an ECP > 9000 %mmHg
(i.e. –2 to −2.2 SD below the level of present young adults)
died during the first year of follow-up [6].
In order to provide a reliable basis for characterizing the
determinants of CP and ECP, we based the technical per-
formance of our study on international standards and cali-
brated devices [1,22,23]. We present the numerical data
on CP and ECP in several alternative ways, which should
help the scientific community to compare the result pro-
files in their own study settings. Based on the relative nor-
mality of our community based cohort, we feel that the
current figures of CP and ECP can be considered to re-
present the average levels of CP and ECP in the general
population. The estimates of CP in our study were very
concordant, irrespective of whether the BP figures were
based on SBP or MAP, rendering both methods of calcula-
tion applicable when the studied indices are formed. We
recommend the use of the predictive equation provided
by either by Wasserman et al. [26] or Koch et al. [25] forthe calculation of the ECP estimates, as these equations
led to very concordant estimates for ECP. We do not rec-
ommend the use of the VO2/SBP ratio to integrate the
cardiac output and BP as this parameter showed the high-
est dependence on subject demographics.
The importance of our preliminary data is emphasized
by the fact that the current values are based on almost
equal numbers of males and females, while in all of the
previous studies described in the above; there is a con-
siderable dominance of male participants. Our study still
leaves many unanswered questions, such as whether CP
and ECP have prognostic power to predict future cardiac
events in unselected cohorts. At this point, we were un-
able to analyze this aspect, as the current morbidity and
mortality rates of our cohort are far too low. However, a
prospective analysis of the predictive power of CPET-
derived parameters for hypertension, myocardial infarc-
tion, stroke and death should be feasible in connection
with later cross-sections of the ongoing follow-up on our
cohort. We hope that our study encourages other re-
searchers to analyze these parameters further in other pa-
tient cohorts, and in healthy, older subjects. The present
data is necessary for the compilation of predictive regres-
sion equations for CP and ECP in the future.
Conclusions
As sex, age, subject anthropometrics and lifestyle had an
effect on CP and ECP; these factors should be taken into
account when the use of CP and ECP is developed
further.
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